Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity by Zis, P et al.
  1 
Title 
Cognitive ability in Down Syndrome and its relationship to urinary neopterin, a 
marker of activated cellular immunity 
Authors 
Panagiotis Zis 1, 2 
André Strydom1, 3 
David Buckley 4  
Daniel Adekitan 4 
Patrick C McHugh 4  
 
Affiliations 
 
1University College London, Division of Psychiatry, London, United Kingdom 
2Sheffield Teaching Hospitals NHS Trust, Department of Neurology, Sheffield, United 
Kingdom 
3The LonDowns Consortium 
4Centre for Biomarker Research, School of Applied Sciences, University of Huddersfield, 
Huddersfield, United Kingdom  
 
 
  
  2 
Abstract 
Background: Neopterin is an unconjugated pteridine that is secreted in large 
quantities by activated macrophages and can be used as a clinical marker of 
activated cellular immunity and oxidative stress. We aimed to investigate whether 
urinary neopterin levels are associated with cognitive function in people with Down 
syndrome (DS).  
Methods: Out of 32 adults with DS who originally participated in a longitudinal study, 
25 were followed up at 4 years. Informants rated their adaptive behavior (ABAS) and 
the adults with DS attempted assessments of language skills and memory at both 
baseline and follow-up time points (Modified Memory Object Task, MOMT), and 
receptive vocabulary (British Picture Vocabulary Scale, BPVS).  
Results: Neopterin/creatinine levels were negatively correlated with change in the 
MOMT total score (Spearman's Rho = -0.517, p =0.020) and change in the MOMT 
delayed recall score (Spearman's Rho = -0.577, p =0.008) over time, i.e. higher 
neopterin/creatinine level was associated with worse performance on a test of 
cognitive ability over time. 
Conclusion: Urine neopterin may have potential as a biomarker for memory decline 
in Down syndrome, and could potentially also help to track progression of mild 
cognitive impairment (MCI) to Alzheimer’s disease in other high risk populations. 
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1. Introduction 
 
Oxidative stress is related to the imbalance between oxidant production and the 
organism’s defenses against its potential damage. In oxidative stress, the organism 
lacks the ability to detoxify the system of reactive oxygen species (ROS) and repair 
the damage they cause. Levels of ROS above the clearance capacity of the body can 
cause mitochondrial dysfunction, cellular damage, and cell death [1]. Oxidative 
stress has been implicated in the pathogenesis of many diseases, including 
Alzheimer’s disease (AD) [2,3].  
In people with Down syndrome (DS), the most common genetic cause of intellectual 
disability (ID), the prevalence of AD increases significantly with age [4]. By the age of 
50, almost all people with DS have neuropathological [5-7] and neuroimaging 
changes characteristic of AD [5, 6]. Although this may be in large part due to the 
triplication of the APP gene in DS, increasing evidence suggests that oxidative stress 
and inflammation may also play a role in AD pathogenesis associated with the 
syndrome [8].  
Neopterin is an unconjugated pteridine that is secreted in large quantities by 
activated macrophages and can be used as a clinical marker of activated cellular 
immunity [9]. Plasma neopterin levels have been found to be higher in patients with 
AD [10, 11] and people with DS [12], with [13] or without [14, 15] dementia. 
Moreover, urinary neopterin levels correlate with cerebrospinal fluid neopterin 
levels in specific patient populations, such as multiple sclerosis patients with positive 
oligoclonal bands [16].  
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We aimed to investigate whether urinary neopterin levels are associated with 
cognitive function in people with DS and whether these levels correlate with 
isoprostane 8,12-iso-iPF2alpha  (iPF2alpha), a urinary marker of oxidative stress. 
2. Methods and Materials 
 
2.1. Study population, iPF2alpha levels, neopterin levels and psychometric 
measurements. 
We used a within-syndrome design to examine the association between urinary 
markers of oxidative stress and changes in cognitive functioning over time in adults 
with DS.  We have previously established a cohort of 32 individuals with DS who 
underwent cognitive testing and donated urine samples for iPF2alpha [17]. The 
patients were followed-up 4 years later [18] when they also donated a urine sample 
for iPF2alpha  [19] and neopterin analysis. Urine spot samples were collected in the 
morning and were stored within 6 hours of collection at -80  C̊. 
Methods for measuring iPF2alpha (corrected for creatinine concentrations) have 
been described elsewhere for both the baseline [17] and the follow-up time points 
[19].  
Urine neopterin levels were measured at follow-up. Urine stored at -80oC was 
initially allowed to thaw at room temperature in the dark, mixed thoroughly by 
repeated inversion, and diluted 1/100 with mobile phase (15mM Potassium 
Phosphate; pH 6.4). Five hundred microlitres of diluted urine was then processed 
through a 0.45µM RC membrane (4mm) syringe filter. Each sample was analysed in 
triplicate with an injection volume of 20µl and the coefficients of variation for 
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neopterin were 4.4% (intra-assay) and 8.6% (inter-assay). Each sample was analysed 
on an Agilent Technologies 1100 system at a flow rate of 1 mL/min using a reversed-
phase SphereClone ODS(2) (4.6 x 250 mm, 5 µm) column coupled to a SecurityGuard 
guard cartridge (Phenomenex). Fluorescence detection of neopterin was performed 
using a 1260 Infinity Fluorescence Detector with an excitation and emission 
wavelength of 353 nm and 438 nm, respectively. Creatinine was detected using an 
Agilent 1100 series UV detector with a wavelength of 235 nm. The concentration of 
neopterin in the urine was then normalised per mole of creatinine. 
Details of the psychometric assessments and population characteristics have also 
been described elsewhere [17 – 19]. In brief, informants (who were in most cases 
family members) completed a measure of adaptive behavior (Adaptive Behaviour 
Assessment Scale; ABAS [20]) and a dementia screen (the cognitive scale of the 
Dementia Scale for people with Learning Disabilities; DLD [21]). The DLD identifies 
individuals who may benefit from a clinical assessment for dementia, but does not 
provide a formal diagnosis. If a difference of 7 points or more on the sum of 
cognitive scores (i.e. short- and long-term memory and orientation) and/or 5 points 
or more on the sum of social scores (i.e. speech, activity, mood, behaviour and 
practical skills) is found between the baseline assessment and subsequent 
assessments, assessment for dementia should be considered [22]. 
Participants who were able to, completed a measure of receptive vocabulary (British 
picture vocabulary scale; BPVS II [23]), and a modification of an object memory task 
(MOMT) based on the Fuld object memory test [24, 25]. We modified the task by 
reducing the number of objects to 6, and the number of trials to two.  
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2.2. Ethics statement and consent procedures  
The study was approved by the National NHS research ethics committee and we 
followed the Mental Capacity Act, UK (2005) if participants did not have the capacity 
to consent for themselves, by gaining agreement from carers. Written informed 
consent or carer’s agreement for participation was obtained for all participants. 
2.3. Data analyses 
Data was analysed with Statistical Package for the Social Sciences (SPSS) [26]. Mann 
Whitney U tests were used to compare scores between groups. Correlations 
between neopterin levels and baseline factors were examined using Spearman’s 
correlations. Correlations between the changes in psychometric and functional 
assessments scores (BPVS, ABAS, MOMT) were examined using Spearman’s 
correlations. The significance level was set at 0.05. 
3. Results 
3.1. Study population 
The original cohort consisted of 32 individuals with DS. Two of the original 
participants refused to participate again, and four were lost to follow-up. All of the 
remaining 26 individuals were followed up. Twenty-five urine samples were available 
for neopterin analysis. The 25 participants (52% females) had a mean age of 36.6  
7.2 years. None was diagnosed with Alzheimer’s disease at baseline. At follow up, 4 
of the 26 individuals screened above threshold on DLD, but did not have a clinical 
diagnosis of AD and upon assessment did not present with sufficient features for a 
DSM-IV or ICD10 diagnosis.  
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3.2. Neopterin, creatinine and iPF2alpha measurements  
At follow-up, urinary neopterin levels ranged from 0.13 to 6.49 µmol/ml (mean 1.79 
± 1.28), urinary creatinine levels ranged from 1.23 to 37.50 mmol/ml (mean 12.75 ± 
9.38) and neopterin levels adjusted for creatinine ranged from 76.82 to 434.89 
µmol/mol creatinine (mean 162.91 ± 84.32). No significant correlation was observed 
between age and urinary neopterin (Spearman’s rho 0.107, p=0.610) or urinary 
creatinine (Spearman’s rho 0.083, p=0.694). 
Data on urinary iPF2alpha were available for 24/26 patients at baseline and for 
25/26 patients at follow-up. At baseline, the range of iPF2alpha was 0.16 to 3.18 
ng/mg creatinine (mean 1.40 ± 0.81) and at follow-up 0.28 to 5.27 ng/mg creatinine 
(mean 1.35 ± 1.22). For the 23/26 patients that had measurement on both time 
points the change between iPF2alpha levels at follow up and at baseline ranged from 
-2.60 to +4.30 ng/mg creatinine (mean 0.007 ± 1.60).  
3.3. Relationship between neopterin and urinary iPF2alpha 
Neopterin/creatinine levels were not correlated significantly with the 
Ipf2alpha/creatinine levels (Spearman’s 0.312, p=0.129). However, 
neopterin/creatinine levels were positively correlated with the change in urinary 
iPF2alpha/creatinine levels over the 4-year period (Spearman’s rho 0.445, p=0.034). 
3.4. Relationship between urinary neopterin/creatinine and cognitive ability changes 
Table 1 lists the correlations between levels of neopterin/creatinine and 
performance over 4 years on tests of functional ability, memory or language ability. 
There were no statistically significant correlations between levels of 
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neopterin/creatinine and change in ABAS total score, change in ABAS functional 
academic score, or change in BPVS score. However, neopterin/creatinine levels were 
negatively correlated with change in the MOMT total score (Spearman's Rho = -
0.517, p =0.020) and change in the MOMT delayed recall score (Spearman's Rho = -
0.577, p =0.008).  
4. Discussion 
 
We have previously shown that change in urinary iPF2alpha/creatinine over time is 
associated with memory decline in people with DS, suggesting that sequential 
measurements of urinary iPF2alpha may have potential as biomarker for cognitive 
decline and progression to AD in this population [19]. In the present study, we have 
explored the relationship between cognitive change over time in adults with DS and 
urinary neopterin, a marker of immune activation, and its relationship to oxidative 
stress.  Compared to other markers of activated cellular immunity and oxidative 
stress, such as isoprostanes, neopterin analysis is relatively low cost which is an 
advantage in both the clinical and the research setting. 
Our results suggest that neopterin/creatinine levels correlate with cognitive ability 
over time suggesting that urinary neopterin may be an early marker of cognitive 
decline in DS. In our study, higher neopterin/creatinine level was associated with 
worse performance on a test of cognitive ability over time (positive difference in the 
MOMT score means improvement and negative difference in the MOMT score 
means deterioration). This finding is consistent with other studies where it has been 
shown that plasma neopterin levels are higher in demented individuals with DS [13] 
and that a high plasma neopterin level is an independent determinant of the risk of 
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dementia in persons with Down syndrome [27]. Plasma neopterin has been shown 
to be increased in healthy adults with DS compared to age and sex matched healthy 
controls [15]. Our results extend these findings by demonstrating that neopterin 
levels may be associated with memory decline before the onset of dementia in this 
population.  
It has been suggested that oxidative stress is an important consequence of the 
specific biology of DS, and is likely to play a role in some of the co-morbidities 
associated with DS, including the tendency to develop AD [28]. Oxidative damage 
may lead to enhanced amyloid beta peptide (Aβ) production [29-33]. Although the 
precise mechanism is still unknown it has been shown that oxidation of proteins is 
an early event in DS and might contribute to neurodegenerative phenomena [34]. 
Although neopterin may play a role as a measure of oxidative stress, since the 
amount of neopterin produced by activated monocytes/macrophages correlates 
with their capacity to release ROS [35], neopterin is primarily a measure of immune 
response [9, 35-37]. Although oxidative damage may be one of the causes of 
inflammation or immune response, it is not necessarily the only cause and, 
therefore, the relationship between neopterin and markers of oxidative stress may 
be partially related to other, unmeasured factors. This may account for our 
observation that there was not direct relationship between neopterin and iPF2alpha 
levels; however, there was a relationship between neopterin levels at follow-up and 
a change in iPF2alpha levels between baseline and follow-up . 
 The strength of our study is that it is – to our knowledge – the first to show that 
urinary neopterin may be used as a biomarker of immune activation due to the 
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pathogenic processes involved in AD in DS, including the effects of oxidative stress, 
and which correlates with cognitive decline over time in this population. 
Our results should be interpreted with some caution given the limitations of our 
design. Firstly, our sample size was relatively small, and our results need to be 
confirmed with a replication larger study. As we have not measured the neopterin 
level at baseline we can only indirectly correlate the neopterin level with cognitive 
decline over time. A prospective cohort study is needed to confirm our findings. 
In conclusion, for the first time, it is suggested that urinary neopterin is correlated 
with cognitive decline DS individuals before the diagnosis of AD. This finding 
strengthens the evidence that peripheral neopterin levels may have potential as a 
biomarker in DS, and in AD. The evidence for the role of immune response and 
oxidative stress in DS is growing and also suggests potential treatment strategies to 
reduce the high risk for AD in this population.  
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